Do I need an in-person exam for Mounjaro in California?

If you’ve been following the surge in popularity of medications like Wegovy, Ozempic, and Mounjaro for weight loss, you’ve probably wondered: Can I actually get these prescriptions through telehealth? The short answer is yes—in most cases. But like many things in healthcare, the details matter, especially when state regulations come into play.

This comprehensive guide will walk you through everything you need to know about accessing GLP-1 weight loss medications via telehealth in 2025, including federal rules, state-specific requirements, and what to expect from your online consultation.

Understanding the Federal Framework: Why Telehealth Access Is Legal

Let’s start with the good news: federal law does not require an in-person visit before prescribing GLP-1 weight loss medications like Wegovy, Ozempic, or Mounjaro through telehealth.

Here’s why: These medications are not controlled substances. The Ryan Haight Act—a federal law that typically mandates in-person exams for certain prescriptions—only applies to controlled medications like Adderall or opioids. Since semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (found in Mounjaro and Zepbound) aren’t classified as controlled substances, they fall outside this restriction.

What Changed During COVID-19?

The pandemic accelerated telehealth adoption across all areas of medicine. In March 2020, the DEA waived in-person requirements even for controlled substances, making virtual prescribing more accessible. While those emergency flexibilities for controlled medications have been extended through December 31, 2025, GLP-1 weight loss drugs were already eligible for telehealth prescribing—pandemic or not.

The real shift was cultural and practical: healthcare providers and patients alike discovered that virtual consultations could deliver quality care while removing barriers like travel time, scheduling conflicts, and geographic limitations.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State Rules: Where Things Get Specific

While federal law permits telehealth prescribing of GLP-1 medications nationwide, individual states add their own layers of requirements. Some states require an initial in-person exam, mandate specific follow-up schedules, or impose documentation standards that go beyond basic medical practice.

States Requiring an Initial In-Person Exam

Several states expect providers to conduct a physical examination before prescribing weight loss medications—even via telehealth programs. These include:

• Arkansas: Known for having some of the nation’s strictest telemedicine regulations, Arkansas requires an initial in-person encounter to establish a valid patient-provider relationship.
• Delaware: State policy mandates a physical exam before telehealth prescribing of weight-loss medications can begin.
• Georgia: Providers must perform an initial in-person evaluation, though follow-up care can continue via telehealth.
• Mississippi: Similar to neighboring states, Mississippi requires at least one in-person visit before initiating treatment.
• New Jersey: The state Board of Medicine requires a comprehensive initial evaluation including physical exam, laboratory work, and psychological screening.
• North Dakota: Expects a hands-on initial evaluation for weight-loss treatment per medical board guidance.
• South Carolina: State obesity treatment policy requires an initial in-person visit and periodic in-person evaluations.
• Texas: While telehealth is broadly permitted, the standard of care typically dictates an initial in-person exam for weight management.
• Utah: State guidelines encourage an in-person baseline evaluation.
• Virginia: Requires an initial physical exam, laboratory tests, and development of a personalized diet and exercise plan.

Important note: Even in these states, telehealth remains valuable. After the initial in-person visit (which can often be with a local provider), ongoing medication management, monitoring, and refills can typically continue through virtual appointments.

States With Additional Requirements Beyond the Initial Visit

Some states go further with ongoing oversight:

Florida stands out with specific rules for obesity medication prescribing:

• Patients must have a BMI of 30 or higher (or 27+ with weight-related health conditions)
• Follow-up visits are required at least once every three months during treatment
• Providers must document lifestyle modification efforts alongside medication

Connecticut requires providers to include behavioral counseling and a diet/exercise plan as part of any obesity treatment prescription.

Virginia mandates a follow-up visit within 30 days of starting therapy to assess tolerance and response.

States With Minimal Telehealth Restrictions

Many states have embraced telehealth for weight management with few special requirements beyond standard medical practice:

• California: Explicitly permits telehealth exams as sufficient; no in-person mandate
• Illinois: No special weight-loss prescribing rules beyond standard care
• New York: Telehealth exam is adequate to establish care
• Washington: No in-person requirements; fully embraces virtual care
• Pennsylvania: No in-person mandate for GLP-1 prescribing

In these states, a thorough telehealth consultation—typically via live video—can establish the patient-provider relationship needed to prescribe weight loss medications.

Who Can Prescribe Your Medication?

The credentials of your telehealth provider matter, and they vary significantly by state.

Physicians (MD/DO)

All states allow licensed physicians to prescribe GLP-1 weight loss medications via telehealth, provided they’re licensed in the state where you’re physically located during the consultation.

Nurse Practitioners (NPs)

This is where state differences become most apparent. As of 2025, 34 states plus Washington D.C. grant Nurse Practitioners full independent practice authority—meaning they can evaluate patients, diagnose conditions, and prescribe medications without physician oversight.

States with full NP independence include:

• California (after 3+ years of experience)
• Connecticut (after 3 years of collaboration)
• Delaware (after 2 years of collaboration)
• New York (after 3,600 hours of practice)
• Utah (as of 2023)
• Virginia (after 2 years)
• Washington

States requiring physician collaboration:

• Arkansas (APRN must have MD agreement)
• Florida (collaborative practice with some independence in primary care)
• Georgia (MD protocol required, though recent law expanded NP authority for certain medications)
• Illinois (written MD agreement required)
• Mississippi (MD collaboration required)
• New Jersey (joint protocol with physician)
• Pennsylvania (collaboration required; full practice regulations still pending)
• South Carolina (MD supervision with written protocol)
• Texas (formal physician agreement required; no independent practice)

Physician Assistants (PAs)

PAs can prescribe GLP-1 medications in all states, but like NPs, they operate under varying degrees of physician supervision depending on state law. Most states require a supervisory or collaborative agreement with a physician.

What this means for you: Whether you see an MD, NP, or PA through telehealth, you can trust they’re operating within their state’s legal framework. Reputable telehealth platforms like Klarity Health credential all providers carefully and ensure they’re licensed and authorized to prescribe in your state.

Your Telehealth Consultation: What to Expect

A legitimate telehealth weight loss consultation should be thorough, not a rubber stamp. Here’s what quality providers will do:

Medical History Review

Expect detailed questions about:

• Current height, weight, and BMI calculation
• Previous weight loss attempts (diet, exercise, other medications)
• Medical conditions, especially thyroid disorders, diabetes, heart disease, or gastrointestinal issues
• Current medications and supplements
• Family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Mental health history, including eating disorders
• Pregnancy status or plans to become pregnant

Clinical Assessment

Your provider will evaluate whether you meet medical criteria for GLP-1 therapy:

• BMI ≥30 (obesity), or
• BMI ≥27 with at least one weight-related health condition (type 2 diabetes, high blood pressure, high cholesterol, sleep apnea)

They’ll also screen for contraindications that would make these medications unsafe, including:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Current pregnancy or breastfeeding
• History of pancreatitis
• Severe gastroparesis or digestive disorders
• Active gallbladder disease

Treatment Planning

If you’re a good candidate, your provider will:

• Explain how the medication works and set realistic expectations (gradual weight loss over months, not weeks)
• Discuss common side effects (nausea, diarrhea, constipation, fatigue)
• Outline the dosing schedule and titration plan
• Emphasize the importance of diet and exercise alongside medication
• Schedule follow-up appointments for monitoring

Documentation and Consent

Expect to receive or review:

• Informed consent explaining risks, benefits, and alternatives
• A personalized treatment plan including lifestyle modifications
• Follow-up schedule (typically monthly initially, then every 2-3 months)
• Prescription sent electronically to your pharmacy

Medication Overview: Wegovy, Ozempic, and Mounjaro

Let’s clarify what these medications are and how they differ:

Key Points About These Medications

Wegovy is FDA-approved specifically for weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It’s administered as a once-weekly injection, with doses gradually increased over 16-20 weeks.

Ozempic contains the same active ingredient as Wegovy but in lower doses and is approved for type 2 diabetes. Many providers prescribe it off-label for weight loss, which is legal but requires documenting the medical rationale and obtaining informed consent from the patient.

Mounjaro and Zepbound both contain tirzepatide, a newer medication that targets both GLP-1 and GIP receptors. Mounjaro is approved for diabetes, while Zepbound received FDA approval specifically for obesity treatment in late 2023. Clinical trials have shown tirzepatide may produce slightly more weight loss than semaglutide.

None of these medications are controlled substances, which is why they’re federally eligible for telehealth prescribing without the in-person requirements that apply to medications like Adderall or pain medications.

The Compounding Controversy: What You Need to Know

If you’ve researched telehealth weight loss programs, you may have encountered offers for ‘compounded semaglutide’ at lower prices than brand-name Wegovy or Ozempic. Here’s what happened:

During shortages of Wegovy and Ozempic in 2022-2024, the FDA allowed compounding pharmacies to create custom versions of semaglutide under a shortage exemption. Many telehealth companies offered these compounded versions at significantly reduced prices.

In May 2025, the FDA declared the shortage over and ended the compounding exemption. This means:

• Compounded semaglutide for weight loss is now generally prohibited
• Telehealth companies can only prescribe FDA-approved brand medications (Wegovy, Ozempic, Mounjaro, Zepbound)
• Some telehealth providers had to discontinue their weight loss programs or significantly raise prices

Red flag: Be wary of any telehealth service still offering ‘compounded’ or ‘custom’ semaglutide. Unless you have a specific medical need that FDA-approved versions can’t meet (which is rare), compounded versions violate current FDA policy. Stick with legitimate, FDA-approved medications dispensed through licensed pharmacies.

Cost and Insurance Considerations

Weight loss medications can be expensive, and insurance coverage varies widely.

Typical Costs Without Insurance

• Wegovy: $1,300-$1,600 per month
• Ozempic: $900-$1,000 per month
• Mounjaro/Zepbound: $1,000-$1,400 per month

Insurance Coverage

Coverage for GLP-1 weight loss medications depends on your specific plan:

Medicare generally does not cover weight loss medications, though it does cover diabetes medications like Ozempic if prescribed for diabetes.

Medicaid coverage varies by state. Some states cover weight loss medications for patients meeting specific criteria.

Private insurance coverage is expanding but inconsistent. Some plans now cover Wegovy and Zepbound for weight management, while others only cover GLP-1s for diabetes treatment.

Manufacturer Savings Programs

All three manufacturers offer savings cards and patient assistance programs:

• Wegovy: Novo Nordisk offers a savings card that may reduce costs to $25 per fill with commercial insurance
• Ozempic: Similar savings card available
• Mounjaro/Zepbound: Eli Lilly offers savings programs potentially reducing costs to $25 per month

Telehealth advantage: Platforms like Klarity Health accept both insurance and cash-pay options, providing transparent pricing upfront so you can make informed decisions. Many telehealth services have also negotiated pharmacy partnerships to help reduce out-of-pocket costs for patients.

Ongoing Monitoring and Follow-Up Care

Getting the prescription is just the beginning. Quality telehealth weight management programs include regular monitoring:

Initial Follow-Up (First 1-2 Months)

Your provider should check in frequently as you start medication:

• Assess tolerance and side effects
• Confirm proper injection technique
• Monitor early weight loss response
• Adjust dosing as needed during titration phase

Ongoing Monitoring (Every 2-3 Months)

Once you’re on a stable dose:

• Weight and BMI tracking
• Review of side effects
• Assessment of weight loss progress
• Evaluation of lifestyle modifications (diet, exercise)
• Periodic laboratory work (metabolic panel, liver function, potentially thyroid hormones)
• Medication refills

Some states mandate specific follow-up schedules (like Florida’s every-three-months requirement), but even where not legally required, regular monitoring is the medical standard of care.

When to Discontinue

Your provider should discuss stopping medication if:

• You haven’t lost at least 5% of body weight after 12-16 weeks at maintenance dose
• Side effects become intolerable
• You develop contraindications (like pregnancy)
• You reach your goal weight and maintain it with lifestyle changes
• You develop concerning lab abnormalities

Red Flags: How to Spot Problematic Telehealth Services

Unfortunately, the popularity of GLP-1 medications has attracted some less-than-reputable operators. Watch out for these warning signs:

⚠️ Guaranteed Prescriptions

No legitimate provider can promise you’ll get a prescription before evaluating your specific situation. If a service guarantees medication regardless of medical history, run the other way.

⚠️ No Live Consultation Required

While asynchronous (questionnaire-only) care has limited uses in telemedicine, prescribing powerful medications for weight loss requires a real-time conversation with a licensed provider. Be suspicious of services that don’t include a video or phone consultation.

⚠️ Compounded or ‘Generic’ Semaglutide

As discussed earlier, compounded semaglutide is no longer legal for routine weight loss use as of 2025. There is no generic version of these medications yet. Only FDA-approved brands should be prescribed.

⚠️ No Follow-Up Plans

Weight loss medication requires ongoing monitoring. Services that don’t schedule regular follow-ups or don’t have a clear plan for tracking your progress aren’t providing complete care.

⚠️ Unclear Provider Credentials

You should be able to easily verify:

• Your provider’s name and credentials (MD, DO, NP, PA)
• Their state medical license number
• Confirmation they’re licensed in your state

⚠️ Prices Too Good to Be True

While telehealth can reduce costs through operational efficiencies, medication prices significantly below market rate may indicate counterfeit drugs, international pharmacies operating outside U.S. regulations, or other problems.

⚠️ Pressure Tactics or Unrealistic Promises

Beware of services promising ‘lose 30 pounds in 30 days’ or using high-pressure sales tactics. Weight loss with GLP-1 medications is gradual and requires commitment to lifestyle changes.

What Makes Klarity Health Different

At Klarity Health, we’ve designed our weight management program around medical best practices and patient accessibility:

Licensed Providers in Your State

All our providers are licensed in the states where they practice, ensuring full compliance with state telehealth laws. Whether you’re in Texas (where we ensure initial in-person exams when required) or California (where we can manage your entire care virtually), we follow your state’s specific rules.

Transparent Pricing

We believe you should know costs upfront. We accept both insurance and cash-pay options, and our team can verify your insurance coverage before your first appointment. No surprise bills.

Comprehensive Care Plans

Our weight management program includes:

• Thorough initial evaluation by a licensed provider
• Personalized treatment plan with lifestyle coaching
• Regular follow-up appointments
• Medication management and titration
• Support from our care team between appointments

Only FDA-Approved Medications

We prescribe only FDA-approved brand medications (Wegovy, Zepbound, or in appropriate cases, Ozempic or Mounjaro). We don’t cut corners with compounded versions or questionable alternatives.

Provider Availability When You Need It

With telehealth, you’re not limited to your local providers’ schedules. Our platform makes it easy to find appointment times that work for you—evenings, weekends, or during your lunch break.

Looking Ahead: The Future of Telehealth Weight Management

The regulatory landscape for telehealth continues to evolve, generally in a direction that expands access while maintaining safety standards.

Federal Developments

The DEA’s temporary telehealth flexibilities for controlled substances (which don’t directly affect GLP-1s but signal overall federal support for telemedicine) are currently extended through December 31, 2025. Bipartisan legislation like the TREATS Act, reintroduced in October 2025, aims to make some telehealth provisions permanent.

These developments suggest strong Congressional and federal agency support for expanding telehealth access across multiple areas of medicine, including weight management.

State Trends

More states are moving toward:

• Full practice authority for Nurse Practitioners: As of 2025, 34 states plus D.C. allow NP independence, up from just a handful a decade ago. Pending legislation in Pennsylvania, Mississippi, and other states could expand this further in 2026.
• Streamlined telehealth requirements: States are increasingly recognizing that many of the pre-pandemic barriers to telemedicine were unnecessary. Expect continued alignment toward more permissive telehealth statutes.
• Interstate licensure compacts: More states are joining agreements that make it easier for providers to obtain licenses in multiple states, expanding telehealth access for patients nationwide.

Medication Pipeline

The weight loss medication landscape is expanding rapidly:

• Several new GLP-1 and dual-receptor agonists are in late-stage clinical trials
• Oral versions of semaglutide are in development (currently only injectable forms are approved for obesity)
• Triple-agonist medications targeting GLP-1, GIP, and glucagon receptors show even more impressive weight loss in early studies

As these medications reach the market, telehealth will likely remain a primary access point, especially for patients in areas with limited obesity medicine specialists.

Common Questions About Telehealth Weight Loss Medication

Can I get weight loss medication if I don’t have any other health conditions?

Yes, if your BMI is 30 or higher, you may qualify for medication even without other conditions like diabetes or high blood pressure. The medications are FDA-approved for obesity treatment alone.

How long does a typical telehealth consultation take?

Initial consultations usually last 20-30 minutes. Follow-up appointments may be shorter (10-15 minutes) once you’re established on medication and doing well.

Can my regular doctor prescribe these medications, or do I need a specialist?

Any licensed physician, NP, or PA can prescribe GLP-1 weight loss medications if authorized in their state. You don’t need to see an obesity medicine specialist, though specialists may have additional expertise in complex cases.

What if I move to a different state while on treatment?

You’ll need a provider licensed in your new state. Many telehealth platforms operate in multiple states and can transition your care. Inform your provider about your move as soon as possible.

Are there age restrictions?

Currently, FDA approval for these medications is for adults age 18 and older. Some formulations are being studied in adolescents, and pediatric approvals may expand in coming years.

How much weight can I realistically expect to lose?

Clinical trials show average weight loss of 10-15% of starting body weight over 12-18 months with semaglutide, and potentially 15-20% with tirzepatide. Individual results vary significantly based on starting weight, adherence to lifestyle changes, and individual metabolism.

Will I regain weight if I stop the medication?

Weight regain is common after stopping these medications, though not universal. Successful long-term weight maintenance typically requires ongoing lifestyle modifications. Some patients may need to stay on medication long-term to maintain weight loss.

Take the Next Step Toward Your Weight Loss Goals

If you’ve been struggling with weight management and wondering whether telehealth could be the right approach, the answer is likely yes—with the right provider and program.

Telehealth removes many traditional barriers to weight loss treatment:

• No waiting months for a specialist appointment: Get an initial consultation within days
• Convenient follow-ups: No taking time off work or arranging childcare for frequent office visits
• Access regardless of location: Whether you live in a rural area or just have a busy schedule, quality care comes to you
• Transparent costs: Know what you’ll pay before you commit

Ready to explore whether GLP-1 medications are right for you? Klarity Health offers comprehensive telehealth weight management with experienced providers licensed in your state. Our team will evaluate your individual situation, answer all your questions, and create a personalized treatment plan that combines medication (if appropriate) with sustainable lifestyle changes.

Schedule your consultation today to take the first step toward achieving your weight loss goals with the convenience and expertise of telehealth care.

References

1. Drug Enforcement Administration. (November 15, 2024). ‘DEA and HHS Extend Telemedicine Flexibilities through 2025.’ Retrieved from www.dea.gov

2. Axios. (November 18, 2024). ‘COVID-era telehealth prescribing extended for controlled substances.’ Retrieved from www.axios.com

3. McDermott Will & Emery LLP. (November 18, 2024). ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025.’ Retrieved from www.mwe.com

4. Goodwin Procter LLP. (March 27, 2024). ‘The Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs.’ Retrieved from www.goodwinlaw.com

5. Reuters. (May 30, 2025). ‘Hims & Hers cuts 4% of workforce amid ban on weight-loss drug copies.’ Retrieved from www.reuters.com

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult with a licensed healthcare provider to determine if GLP-1 medications are appropriate for your individual situation. Telehealth services must comply with all applicable federal and state laws, and providers must be licensed in the state where the patient is located.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid